EPA:ALBPS - Euronext Paris - Matif - FR001400OLP5 - Common Stock - Currency: EUR
EPA:ALBPS (3/7/2025, 7:00:00 PM)
0.3
+0 (+1.35%)
The current stock price of ALBPS.PA is 0.3 EUR. In the past month the price increased by 2.92%. In the past year, price decreased by -81.71%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B |
Biophytis SA is a FR-based company operating in Biotechnology industry. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2015-07-13. Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
BIOPHYTIS
14 avenue de l'Opera
Paris ILE-DE-FRANCE FR
Employees: 22
Company Website: https://www.biophytis.com/
Investor Relations: http://www.biophytis.com/en/action/operation-publique-de-bsa/
Phone: 33141836600
The current stock price of ALBPS.PA is 0.3 EUR. The price increased by 1.35% in the last trading session.
The exchange symbol of BIOPHYTIS is ALBPS and it is listed on the Euronext Paris - Matif exchange.
ALBPS.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed ALBPS.PA and the average price target is 0.84 EUR. This implies a price increase of 178.8% is expected in the next year compared to the current price of 0.3. Check the BIOPHYTIS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOPHYTIS (ALBPS.PA) has a market capitalization of 3.44M EUR. This makes ALBPS.PA a Nano Cap stock.
BIOPHYTIS (ALBPS.PA) currently has 22 employees.
BIOPHYTIS (ALBPS.PA) has a support level at 0.3 and a resistance level at 0.31. Check the full technical report for a detailed analysis of ALBPS.PA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALBPS.PA does not pay a dividend.
BIOPHYTIS (ALBPS.PA) will report earnings on 2025-04-07, after the market close.
BIOPHYTIS (ALBPS.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.54).
ChartMill assigns a technical rating of 1 / 10 to ALBPS.PA. When comparing the yearly performance of all stocks, ALBPS.PA is a bad performer in the overall market: 98.25% of all stocks are doing better.
Over the last trailing twelve months ALBPS.PA reported a non-GAAP Earnings per Share(EPS) of -6.54. The EPS decreased by -8080.37% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -172.99% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 84% to ALBPS.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.